Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Troriluzole - Biohaven Pharmaceuticals

Next Previous
Drug Profile

Troriluzole - Biohaven Pharmaceuticals

Alternative Names: BHV-4157; BHV-4157a; Dazluma; FC 4157; trigriluzole; Trigriluzole-Biohaven Pharmaceuticals; Troriluzole-hydrochloride

Latest Information Update: 21 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company; Biohaven Pharmaceuticals; Global Coalition for Adaptive Research; National Cancer Institute (USA); Rutgers Cancer Institute of New Jersey
  • Class Acetamides; Amines; Antidementias; Antineoplastics; Anxiolytics; Behavioural disorder therapies; Benzothiazoles; Fluorinated hydrocarbons; Neuroprotectants; Peptides; Small molecules
  • Mechanism of Action Excitatory amino acid antagonists; Glutamate release inhibitors; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Spinocerebellar degeneration
  • Phase III Obsessive-compulsive disorders
  • Phase II/III Alzheimer's disease; Glioblastoma
  • Phase II Malignant melanoma
  • No development reported Lymphoma; Solid tumours
  • Discontinued Anxiety disorders

Most Recent Events

  • 14 Nov 2023 Preregistration for Spinocerebellar degeneration in European Union (PO)
  • 14 Nov 2023 EMA validates the Marketing Authorization Application (MAA) for troriluzole for Spinocerebellar degeneration
  • 13 Sep 2023 Biohaven initiates an expanded access program to provide troriuzole for treatment of Spinocerebellar degeneration (PO) in September 2023 (NCT06034886)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top